Diagnostic utility of different MRI and MR angiography measures in Fabry disease

Neurology

Volumn 72, Issue 1, 2009, Pages 63-68

  Fellgiebel, A ^a,d   Keller, I ^a,b   Marin, D ^a   Muller M J ^a   Schermuly, I ^a   Yakushev, I ^a   Albrecht, J ^a   Bellhauser H ^a   Kinateder, M ^a   Beck, M ^c   Stoeter, P ^b  

^a Department of Psychiatry ^*  (Germany)

^b Universitaetsmedizin Goettingen   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTERY DIAMETER; ARTICLE; BASILAR ARTERY; BRAIN ARTERY; BRAIN DAMAGE; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; FABRY DISEASE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CEREBRAL ARTERY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WHITE MATTER; AREA UNDER THE CURVE; BRAIN; BRAIN ANGIOGRAPHY; BRAIN MAPPING; CASE CONTROL STUDY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; THREE DIMENSIONAL IMAGING;

ADULT; AREA UNDER CURVE; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; CEREBRAL ANGIOGRAPHY; CEREBRAL ARTERIES; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FABRY DISEASE; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 63849192341     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000338566.54190.8a     Document Type: Article

References (24)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281: 249-254.
2. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242.
3. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006;5:791-795.
4. Fellgiebel A, Mazanek M, Whybra C, et al. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780-787.
5. Albrecht J, Dellani PR, Müller MJ, et al. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 2007;78:964-969.
6. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257:258-263.
7. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40 :8-17.
8. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003;24:1096-1101.
9. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346.
10. Villablanca JP, Nael K, Habibi R, Nael A, Laub G, Finn JP. 3 T contrast-enhanced magnetic resonance angiography for evaluation of the intracranial arteries: comparison with time-of-flight magnetic resonance angiography and multislice computed tomography angiography. Invest Radiol 2006;41:799-805.
11. Tarasow E, Abdulwahed Saleh Ali A, Lewszuk A, Walecki J. Measurements of the middle cerebral artery in digital subtraction angiography and MR angiography. Med Sci Monit 2007;13 Suppl 1:65-72.
12. Anderson CM, Lee RE, Levin DL, de la Torre Alonso S, Saloner D. Measurement of internal carotid artery stenosis from source MR angiograms. Radiology 1994;193:219-226.
13. Kretschmann WJ, Weinrich W. Klinische Neuroanatomie und kranielle Bilddiagnostik. 2. ed. Stuttgart: Thieme Verlag; 1991.
14. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-1796.
15. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
16. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65: 600-602.
17. Bisschops RH, van der Graaf Y, Mali WP, van der Grond J. High total cerebral blood flow is associated with a decrease of white matter lesions. J Neurol 2004;251:1481-1485.
18. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005;84:261-268.
19. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251:564-570.
20. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62:231-240.
21. Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 2001;11:303-307.
22. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506-1512.
23. Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34:838-844.
24. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-531.